ArticleTropical medicine and health2026
Human and livestock exposure to Rift Valley fever virus and Coxiella burnetii in Eastern Ethiopia: a One Health cross-sectional study.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rift Valley Fever at Europe's Risk Frontier: Climate, Vectors, and One Health Preparedness.Veterinary sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRift Valley fever (RVF) virus and Coxiella burnetii are high-priority zoonotic pathogens posing health and economic threats in Africa. Data from Ethiopia are limited. This study estimated the prevalence and associated factors of RVF virus and C. burnetii among humans and livestock in Eastern Ethiopia using a One Health approach.
methodsA multi-site cross-sectional study was conducted from May 1 to November 30, 2023, in the Shinile district, Somali Region, and Dire Dawa Administration. Data and blood samples were collected from 512 humans, and blood samples were collected from 1130 livestock. Sera and nucleic acids were tested using enzyme-linked immunosorbent assays (ELISA) and polymerase chain reaction (PCR), respectively. Logistic regression models were used to identify factors associated with RVF virus and C. burnetii IgG seropositivity.
resultsApparent RVF virus IgG seroprevalence was 5.1% (26/512) in humans and 7.8% (88/1130) in livestock, while C. burnetii Phase I and II IgG seroprevalence was 30.3% (155/512) and 32.9% (372/1130), respectively. Camels showed the highest seropositivity to RVF virus IgG (17.7%; 52/294) and C. burnetii Phase I and II IgG (39.5%; 116/294). Co-seropositivity was 1.8% (9/512) in humans and 3.7% (42/1,130) in livestock. All PCR tests were negative. Rift Valley fever virus IgG seropositivity was associated with handling aborted materials (OR = 3.7; 95% CI 1.4-9.6; p = 0.007) and high mosquito abundance (OR = 4.5; 95% CI 2.0-10.1; p < 0.001). Camels had the highest odds of RVF virus IgG seropositivity (OR = 8.0, 95% CI 3.5-18.2; p < 0.001). Human C. burnetii Phase I and II IgG seropositivity was associated with female sex (OR = 2.4; 95% CI 1.6-3.6; p < 0.001), raw milk consumption (OR = 2.2; 95% CI 1.4-3.5; p < 0.001), cohabitation with animals (OR = 1.7; 95% CI 1.1-2.5; p = 0.01), and handling animal carcasses (OR = 2.3; 95% CI 1.4-3.5; p < 0.001).
conclusionsThe seroprevalence of RVF virus was low, whereas the seroprevalence of C. burnetii was high. High camel seropositivity underscores their role in pathogen transmission. One Health surveillance and targeted interventions are recommended to control the risk of future outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.